2
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Conditions
Lambert-Eaton Myasthenic Syndrome
10
Myasthenic Syndromes, Congenital
3
Myasthenia Gravis
3
Rare Diseases
1
Nystagmus, Pathologic
1
Neurologic Manifestations
1
Mental Disorders
1
Interventions
Amifampridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Nystagmus, Pathologic
×
Amifampridine
×
Clear all
NCT02189720
2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing